
Am J Psychiatry 163:1519-1530, September 2006
doi: 10.1176/appi.ajp.163.9.1519
© 2006 American Psychiatric Association
A Comparison of Lithium and T3 Augmentation Following Two Failed Medication Treatments for Depression: A STAR*D Report
Andrew A. Nierenberg, M.D.,
Maurizio Fava, M.D.,
Madhukar H. Trivedi, M.D.,
Stephen R. Wisniewski, Ph.D.,
Michael E. Thase, M.D.,
Patrick J. McGrath, M.D.,
Jonathan E. Alpert, M.D., Ph.D.,
Diane Warden, Ph.D., M.B.A.,
James F. Luther, M.A.,
George Niederehe, Ph.D.,
Barry Lebowitz, Ph.D.,
Kathy Shores-Wilson, Ph.D., and
A. John Rush, M.D.
STAR*D Study Team
OBJECTIVE: More than 40% of patients with major depressive disorder do not achieve remission even after two optimally delivered trials of antidepressant medications. This study compared the effectiveness of lithium versus triiodothyronine (T3) augmentation as a third-step treatment for patients with major depressive disorder. METHOD: A total of 142 adult outpatients with nonpsychotic major depressive disorder who had not achieved remission or who were intolerant to an initial prospective treatment with citalopram and a second switch or augmentation trial were randomly assigned to augmentation with lithium (up to 900 mg/day; N=69) or with T3 (up to 50 µg/day; N=73) for up to 14 weeks. The primary outcome measure was whether participants achieved remission, which was defined as a score 7 on the 17-item Hamilton Depression Rating Scale. RESULTS: After a mean of 9.6 weeks (SD=5.2) of treatment, remission rates were 15.9% with lithium augmentation and 24.7% with T3 augmentation, although the difference between treatments was not statistically significant. Lithium was more frequently associated with side effects (p=0.045), and more participants in the lithium group left treatment because of side effects (23.2% versus 9.6%; p=0.027). CONCLUSIONS: Remission rates with lithium and T3 augmentation for participants who experienced unsatisfactory results with two prior medication treatments were modest and did not differ significantly. The lower side effect burden and ease of use of T3 augmentation suggest that it has slight advantages over lithium augmentation for depressed patients who have experienced several failed medication trials.
Related Article:
-
In This Issue
Am J Psychiatry 2006 163: 64.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
A. J. Rush MD
Developing the evidence for evidence-based practice
Can. Med. Assoc. J.,
May 6, 2008;
178(10):
1313 - 1315.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Clayton and T. Auster
Strategies for the Prevention and Treatment of Suicidal Behavior
Focus,
January 1, 2008;
6(1):
15 - 21.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Bibliography for Major Depressive Disorder and Suicide
Focus,
January 1, 2008;
6(1):
58 - 62.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. J. Rush, M. H. Trivedi, S. R. Wisniewski, A. A. Nierenberg, J. W. Stewart, D. Warden, G. Niederehe, M. E. Thase, P. W. Lavori, B. D. Lebowitz, et al.
Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report
Focus,
January 1, 2008;
6(1):
128 - 142.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Cooper-Kazaz, J. T. Apter, R. Cohen, L. Karagichev, S. Muhammed-Moussa, D. Grupper, T. Drori, M. E. Newman, H. A. Sackeim, B. Glaser, et al.
Combined Treatment With Sertraline and Liothyronine in Major Depression: A Randomized, Double-blind, Placebo-Controlled Trial
Arch Gen Psychiatry,
June 1, 2007;
64(6):
679 - 688.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. HEATH
Reactive Depression and Remission Rates in the STAR*D Trials
Am J Psychiatry,
April 1, 2007;
164(4):
680 - 681.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Ehret and B. Chavez
A Review of the STAR*D Trial
Journal of Pharmacy Practice,
December 1, 2006;
19(6):
353 - 360.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
A. J. Rush, M. H. Trivedi, S. R. Wisniewski, A. A. Nierenberg, J. W. Stewart, D. Warden, G. Niederehe, M. E. Thase, P. W. Lavori, B. D. Lebowitz, et al.
Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report
Am J Psychiatry,
November 1, 2006;
163(11):
1905 - 1917.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Still More Results from a Large Depression Trial
Journal Watch (General),
October 19, 2006;
2006(1019):
2 - 2.
[Full Text]
|
 |
|

|
 |

|
 |
 
More on STAR*D's Trials (and Tribulations)
Journal Watch Psychiatry,
October 16, 2006;
2006(1016):
3 - 3.
[Full Text]
|
 |
|

|
 |

|
 |
 
Bibliography PSYCHOPHARMACOLOGY
Focus,
September 1, 2006;
4(4):
512.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Abstracts PSYCHOPHARMACOLOGY
Focus,
September 1, 2006;
4(4):
515.
[Full Text]
[PDF]
|
 |
|
Get information about faster international access.
a>
Privacy Policy
Copyright © 2006
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|